Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CD81 | P60033 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2059972 | 0.80 | TSHR (0.33) | FAAHALDH1A1CYP2D6CYP2C19TSHR | |
| SCHEMBL2144011 | 0.75 | CYP2D6 (0.34) | ALDH1A1CYP2D6CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL10325236 | 0.73 | TSHR (0.38) | FAAHALDH1A1TSHRSMN1; SMN2MAPT | |
| SCHEMBL10325251 | 0.72 | THRB (0.37) | ALDH1A1TSHRSMN1; SMN2MAPT | |
| SCHEMBL11341491 | 0.72 | CYP2D6 (0.41) | ALDH1A1CYP2D6CYP2C19CD81 | |
| SCHEMBL8928163 | 0.70 | SMN1; SMN2 (0.41) | FAAHALDH1A1TSHRSMN1; SMN2MAPT | |
| SCHEMBL1282758 | 0.68 | SMN1; SMN2 (0.42) | FAAHALDH1A1CYP2D6CYP2C19TSHR | |
| SCHEMBL1401881 | 0.68 | CD81 (0.41) | ALDH1A1CYP2D6CYP2C19TSHRMAPT | |
| SCHEMBL1489811 | 0.67 | POLB (0.39) | ALDH1A1CYP2D6CYP2C19SMN1; SMN2CD81 | |
| SCHEMBL9680823 | 0.67 | TSHR (0.41) | FAAHALDH1A1TSHRSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238661-A1 | Processes for the Synthesis of Compounds from Cyclic Carbonates | COGNIS IP MANAGEMENT GMBH (DE) | 2012-09-20 | — | — | US | disclosed |
| WO-2012095293-A2 | PROCESS FOR THE SYNTHESIS OF COMPOUNDS FROM CYCLIC CARBONATES | COGNIS IP MANAGEMENT GMBH (DE) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238661-A1 | Processes for the Synthesis of Compounds from Cyclic Carbonates | GK, CRYZ, ELOC | FAAH 1432/4885ALDH1A1 3734/4885CYP2D6 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.